BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAFV600E Mutation Test in Papillary Thyroid Carcinoma
Authors:
- 10 May 2015
- journal article
- research article
- Published by Springer Nature in Endocrine Pathology
- Vol. 26 (3) , 211-217
Abstract
The aim of this study was to investigate the concordance between BRAFV600E mutation test and immunohistochemistry (IHC) and determine the diagnostic accuracy of IHC for papillary thyroid carcinoma (PTC) through a systematic review, meta-analysis, and diagnostic test accuracy review. The current systematic review and meta-analysis included 1141 PTCs in 11 eligible studies. We investigated the concordance rate and performed subgroup analysis using tissue and cytologic samples. Diagnostic test accuracy review was conducted and calculated using the value of area under curve (AUC) on the summary receiver operating characteristic (SROC) curve. The positive rate of BRAF IHC was 79.1 % (903 of 1141 cases), and the BRAFV600E mutation was found in 76.6 % (874 of 1141 cases). The concordance rates were 0.921 (95 % confidence interval (CI) 0.877–0.950) and 0.894 (95 % CI 0.801–0.946) in IHC positive and negative subgroups, respectively. In the diagnostic test accuracy review, the pooled sensitivity and specificity were 0.97 (95 % CI 0.95–0.98) and 0.78 (95 % CI 0.72–0.83). The value of AUC on SROC curve was 0.983, and diagnostic odds ratio was 164.28 (95 % CI 57.69–467.80). Our results showed that BRAF IHC was strongly concordant with BRAF mutation test and had high diagnostic accuracy in BRAF mutation analysis of PTC.Keywords
This publication has 28 references indexed in Scilit:
- Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of ciliaLaboratory Investigation, 2015
- BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysisEndocrine-Related Cancer, 2015
- Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinomaPathology, 2014
- Morphological parameters able to predict BRAFV600E‐mutated malignancies on thyroid fine‐needle aspiration cytology: Our institutional experienceCancer Cytopathology, 2014
- A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinomaHuman Pathology, 2014
- The prognostic significance of the BRAFV600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistryPathology, 2013
- Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinomaSurgery, 2013
- Utilization of a MAB for BRAFV600E detection in papillary thyroid carcinomaEndocrine-Related Cancer, 2012
- BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical ImplicationsEndocrine Reviews, 2007
- No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in TaiwanClinical Endocrinology, 2005